BioCentury
ARTICLE | Company News

arGentis, University of Tennessee deal

November 16, 2009 8:00 AM UTC

arGentis received exclusive, worldwide rights to the university's ARG301 to treat rheumatoid arthritis. The oral synthetic peptide targeting Type II collagen is in preclinical development. Financial ...